Understanding the role of gut microfloral bifidobacterium in cancer and its potential therapeutic applications

Abstract

Gut microbiota research has gained a tremendous amount of attention from the scientific community because of its contribution to gut homeostasis, human health, and various pathophysiological conditions. The early colonizer of the human gut, i.e., bifidobacteria, has emerged as an efficient probiotic in various diseased conditions, including cancer. This review explores the pros and cons of Bifidobacterium in various malignancies and various therapeutic strategies. We have illustrated the controversial role of bifidobacteria participating in various malignancies as well as described the current knowledge regarding its use in anticancer therapies. Ultimately, this article also addresses the need for further extensive research in elucidating the mechanism of how bifidobacteria is involved and is indirectly affecting the tumor microenvironment. Exhaustive and large-scale research is also required to solve the controversial questions regarding the involvement of bifidobacteria in cancer research.

Keywords

Bifidobacterium / gut microbiota / homeostasis / chemotherapy / carcinogenesis

References

[1] Sgorbati B,Palenzona D.The genus Bifidobacterium. In: Wood BJB, Holzapfel WH, editors. The Genera of Lactic Acid Bacteria. Boston: Springer US; 1995. p. 279-306.

[2] Colston JM,Ahmed T.Intestinal colonization with Bifidobacterium longum subspecies is associated with length at birth, exclusive breastfeeding, and decreased risk of enteric virus infections, but not with histo-blood group antigens, oral vaccine response or later growth in three birth cohorts.Front Pediatr2022;10:804798 PMCID:PMC8888871

[3] Dominguez-Bello MG,Contreras M.Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns.Proc Natl Acad Sci U S A2010;107:11971-5 PMCID:PMC2900693

[4] Guaraldi F.Effect of breast and formula feeding on gut microbiota shaping in newborns.Front Cell Infect Microbiol2012;2:94 PMCID:PMC3472256

[5] Nowak A,Błasiak J.Anti-proliferative, pro-apoptotic and anti-oxidative activity of Lactobacillus and Bifidobacterium strains: a review of mechanisms and therapeutic perspectives.Crit Rev Food Sci Nutr2019;59:3456-67

[6] Coutzac C,Paci A.Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer.Nat Commun2020;11:2168 PMCID:PMC7195489

[7] Asadollahi P,Rohani M,Esghaei M.Anti-cancer effects of Bifidobacterium species in colon cancer cells and a mouse model of carcinogenesis.PLoS One2020;15:e0232930 PMCID:PMC7219778

[8] Yoon Y,Jeon BN,Park H.Bifidobacterium strain-specific enhances the efficacy of cancer therapeutics in tumor-bearing mice.Cancers2021;13:957 PMCID:PMC7956760

[9] Wu J,Zheng B,Wang H.Modulation of gut microbiota to enhance effect of checkpoint inhibitor immunotherapy.Front Immunol2021;12:669150 PMCID:PMC8276067

[10] Vétizou M,Daillère R.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.Science2015;350:1079-84 PMCID:PMC4721659

[11] Li W,Liu J.Nanodrug-loaded Bifidobacterium bifidum conjugated with anti-death receptor antibody for tumor-targeted photodynamic and sonodynamic synergistic therapy.Acta Biomater2022;146:341-56

[12] Benito I,Milagro FI.Microencapsulated Bifidobacterium bifidum and Lactobacillus gasseri in combination with quercetin inhibit colorectal cancer development in Apc^Min/+ mice.Int J Mol Sci2021;22:4906 PMCID:PMC8124226

[13] Hill C,Reid G.Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic.Nat Rev Gastroenterol Hepatol2014;11:506-14

[14] Gleinser M,Zhurina D,Riedel CU.Improved adhesive properties of recombinant bifidobacteria expressing the Bifidobacterium bifidum-specific lipoprotein BopA.Microb Cell Fact2012;11:80 PMCID:PMC3408352

[15] Kavanaugh DW,Buttó LF.Exposure of Bifidobacterium longum subsp. infantis to milk oligosaccharides increases adhesion to epithelial cells and induces a substantial transcriptional response.PLoS One2013;8:e67224 PMCID:PMC3689703

[16] Foroni E,Amidani D.Genetic analysis and morphological identification of pilus-like structures in members of the genus Bifidobacterium.Microb Cell Fact2011;10 Suppl 1:S16 PMCID:PMC3231923

[17] Sarkar A.Bifidobacteria-insight into clinical outcomes and mechanisms of its probiotic action.Microbiol Res2016;192:159-71

[18] Alp G.Relationship between the resistance to bile salts and low pH with exopolysaccharide (EPS) production of Bifidobacterium spp. isolated from infants feces and breast milk.Anaerobe2010;16:101-5

[19] Chiu Y,Lin S,Lin M.Characterisation of bifidobacteria with immunomodulatory properties isolated from human breast milk.J Funct Foods2014;7:700-8

[20] Bermudez-Brito M,Gomez-Llorente C.Cell-free culture supernatant of Bifidobacterium breve CNCM I-4035 decreases pro-inflammatory cytokines in human dendritic cells challenged with Salmonella typhi through TLR activation.PLoS One2013;8:e59370 PMCID:PMC3595273

[21] Meng H,Lee Y.Consumption of Bifidobacterium animalis subsp. lactis BB-12 in yogurt reduced expression of TLR-2 on peripheral blood-derived monocytes and pro-inflammatory cytokine secretion in young adults.Eur J Nutr2017;56:649-61

[22] Mortaz E,Ricciardolo FL.Anti-inflammatory effects of lactobacillus rahmnosus and Bifidobacterium breve on cigarette smoke activated human macrophages.PLoS One2015;10:e0136455 PMCID:PMC4552661

[23] Yang X,Liu J.Effect of EPEC endotoxin and bifidobacteria on intestinal barrier function through modulation of toll-like receptor 2 and toll-like receptor 4 expression in intestinal epithelial cell-18.World J Gastroentero2017;23:4744-51

[24] Becerra JE,Rodríguez-Díaz J,Yebra MJ.Preparative scale purification of fucosyl-N-acetylglucosamine disaccharides and their evaluation as potential prebiotics and antiadhesins.Appl Microbiol Biotechnol2015;99:7165-76

[25] Chichlowski M,German JB,Mills DA.Bifidobacteria isolated from infants and cultured on human milk oligosaccharides affect intestinal epithelial function.J Pediatr Gastroenterol Nutr2012;55:321-7 PMCID:PMC3381975

[26] Collado MC,Sanz Y.Adhesion properties and competitive pathogen exclusion ability of bifidobacteria with acquired acid resistance.J Food Prot2006;69:1675-9

[27] Vazquez-Gutierrez P,Jaeggi T,Zimmerman MB.Bifidobacteria strains isolated from stools of iron deficient infants can efficiently sequester iron.BMC Microbiol2015;15:3 PMCID:PMC4320568

[28] Liévin V,Hudault S.Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity.Gut2000;47:646-52 PMCID:PMC1728100

[29] Bali V,Bera MB.Bacteriocins: recent trends and potential applications.Crit Rev Food Sci Nutr2016;56:817-34

[30] Liu G,Song Z,Sun B.Purification and characteristics of bifidocin A, a novel bacteriocin produced by Bifidobacterium animals BB04 from centenarians’ intestine.Food Control2015;50:889-95

[31] Klaenhammer TR.Genetics of bacteriocins produced by lactic acid bacteria.FEMS Microbiol Rev1993;12:39-85

[32] Collado MC,González R,Ferrús MA.Antimicrobial peptides are among the antagonistic metabolites produced by Bifidobacterium against Helicobacter pylori.Int J Antimicrob Agents2005;25:385-91

[33] Heravi F, Hu H. Bifidobacterium: host-microbiome interaction and mechanism of action in preventing common gut-microbiota-associated complications in preterm infants: a narrative review.Nutrients2023;15:709 PMCID:PMC9919561

[34] Fukuda S,Hase K.Bifidobacteria can protect from enteropathogenic infection through production of acetate.Nature2011;469:543-7

[35] Matsuki T,Regnault B,Hara T.Epithelial cell proliferation arrest induced by lactate and acetate from Lactobacillus casei and Bifidobacterium breve.PLoS One2013;8:e63053 PMCID:PMC3639975

[36] Bindels LB,Dewulf EM.Gut microbiota-derived propionate reduces cancer cell proliferation in the liver.Br J Cancer2012;107:1337-44 PMCID:PMC3494429

[37] Ravishankar RV. Beneficial microbes in fermented and functional foods. Boca Raton, FL: CRC Press; 2015. Available from: https://www.taylorfrancis.com/books/edit/10.1201/b17912/beneficial-microbes-fermented-functional-foods-ravishankar-rai-jamuna-bai. [Last accessed on 31 Oct 2023]

[38] Vancamelbeke M.The intestinal barrier: a fundamental role in health and disease.Expert Rev Gastroenterol Hepatol2017;11:821-34 PMCID:PMC6104804

[39] Hsieh CY,Moriyama E,Kikuchi J.Strengthening of the intestinal epithelial tight junction by Bifidobacterium bifidum.Physiol Rep2015;3:e12327 PMCID:PMC4393161

[40] Ulluwishewa D,McNabb WC,Wells JM.Regulation of tight junction permeability by intestinal bacteria and dietary components.J Nutr2011;141:769-76

[41] Ling X,Weixia D.Protective effects of Bifidobacterium on intestinal barrier function in LPS-induced enterocyte barrier injury of Caco-2 monolayers and in a rat NEC model.PLoS One2016;11:e0161635 PMCID:PMC4995054

[42] Al-Sadi R,Nighot P.Bifidobacterium bifidum enhances the intestinal epithelial tight junction barrier and protects against intestinal inflammation by targeting the toll-like receptor-2 pathway in an NF-κB-independent manner.Int J Mol Sci2021;22:8070 PMCID:PMC8347470

[43] Tojo R,Clemente MG.Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis.World J Gastroenterol2014;20:15163-76 PMCID:PMC4223251

[44] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[45] Lauren P.The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification.Acta Pathol Microbiol Scand1965;64:31-49

[46] Sarhadi V,Kokkola A.Gut microbiota of patients with different subtypes of gastric cancer and gastrointestinal stromal tumors.Gut Pathog2021;13:11 PMCID:PMC7888145

[47] Sivan A,Hubert N.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.Science2015;350:1084-9 PMCID:PMC4873287

[48] Feldman M,Brandt LJ. Sleisenger and fordtran’s gastrointestinal and liver disease. Available from: https://www.sciencedirect.com/book/9781416061892/sleisenger-and-fordtrans-gastrointestinal-and-liver-disease. [Last accessed on 31 Oct 2023]

[49] Devi TB,George M.Low Bifidobacterium abundance in the lower gut microbiota is associated with helicobacter pylori-related gastric ulcer and gastric cancer.Front Microbiol2021;12:631140 PMCID:PMC7953064

[50] Arboleya S,Stanton C.Gut bifidobacteria populations in human health and aging.Front Microbiol2016;7:1204 PMCID:PMC4990546

[51] Choi Y,Kim KW.Gastric cancer in older patients: a retrospective study and literature review.Ann Geriatr Med Res2022;26:33-41 PMCID:PMC8984166

[52] Cancer.Net. Stomach Cancer: Risk Factors. Available from: https://www.cancer.net/cancer-types/stomach-cancer/risk-factors. [Last accessed on 31 Oct 2023]

[53] Hu JX,Chen WB.Pancreatic cancer: a review of epidemiology, trend, and risk factors.World J Gastroenterol2021;27:4298-321 PMCID:PMC8316912

[54] Wang XY,Makale EC.Gut microbial profile in patients with pancreatic cancer.Jundishapur J Microbiol2022;15:e122386

[55] Szkandera J,Eisner F.External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients.PLoS One2013;8:e78225 PMCID:PMC3817201

[56] Kim Y,Kim D.Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by Bifidobacterium adolescentis SPM0212.Arch Pharm Res2008;31:468-73

[57] Deo SVS,Kumar S.GLOBOCAN 2020 report on global cancer burden: challenges and opportunities for surgical oncologists.Ann Surg Oncol2022;29:6497-500

[58] Youssef O,Kokkola A.Stool microbiota composition differs in patients with stomach, colon, and rectal neoplasms.Dig Dis Sci2018;63:2950-8 PMCID:PMC6182444

[59] Wang Z.Effects of folic acid deficiency on genetic damage in colorectal cancer cells.Am J Transl Res2023;15:3162-71 PMCID:PMC10250996

[60] Kim Y.Current status of folic acid supplementation on colorectal cancer prevention.Curr Pharmacol Rep2016;2:21-33

[61] Sugahara H,Hashikura N,Xiao JZ.Differences in folate production by bifidobacteria of different origins.Biosci Microbiota Food Health2015;34:87-93 PMCID:PMC4654071

[62] Waszkiewicz N,Konarzewska-Duchnowska E.Serum β-glucuronidase as a potential colon cancer marker: a preliminary study.Postepy Hig Med Dosw2015;69:436-9

[63] Molan AL,Plimmer G.Evaluation of the effect of blackcurrant products on gut microbiota and on markers of risk for colon cancer in humans.Phytother Res2014;28:416-22

[64] Webb PM.Epidemiology of epithelial ovarian cancer.Best Pract Res Clin Obstet Gynaecol2017;41:3-14

[65] D’Amico F,Rampelli S.Gut microbiota dynamics during chemotherapy in epithelial ovarian cancer patients are related to therapeutic outcome.Cancers2021;13:3999 PMCID:PMC8393652

[66] Warburg O.On the origin of cancer cells.Science1956;123:309-14

[67] Falzone L,Libra M.Evolution of cancer pharmacological treatments at the turn of the third millennium.Front Pharmacol2018;9:1300 PMCID:PMC6243123

[68] Badgeley A,Modi K,Lakshmikuttyamma A.Effect of probiotics and gut microbiota on anti-cancer drugs: mechanistic perspectives.Biochim Biophys Acta Rev Cancer2021;1875:188494

[69] Wada M,Saito M.Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies.Support Care Cancer2010;18:751-9

[70] Mi H,Zhang B.Bifidobacterium infantis ameliorates chemotherapy-induced intestinal mucositis via regulating T cell immunity in colorectal cancer rats.Cell Physiol Biochem2017;42:2330-41

[71] Zaharuddin L,Muhammad Nawawi KN.A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer.BMC Gastroenterol2019;19:131 PMCID:PMC6657028

[72] Mizuta M,Yamamoto S.Perioperative supplementation with bifidobacteria improves postoperative nutritional recovery, inflammatory response, and fecal microbiota in patients undergoing colorectal surgery: a prospective, randomized clinical trial.Biosci Microbiota Food Health2016;35:77-87 PMCID:PMC4858881

[73] Liu J.Efficacy of Bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation.Asian Pac J Cancer Prev2014;15:10241-4

[74] Yang J,Chen Y.Pre-treatment with Bifidobacterium infantis and its specific antibodies enhance targeted radiosensitization in a murine model for lung cancer.J Cancer Res Clin Oncol2021;147:411-22

[75] Arunachalam KD.Role of Bifidobacteria in nutrition, medicine and technology.Nutrition Research1999;19:1559-97

[76] Cronin M,Rajendran S.Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors.Mol Ther2010;18:1397-407 PMCID:PMC2911250

[77] Yazawa K,Amano J,Taniguchi S.Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors.Cancer Gene Ther2000;7:269-74

[78] Michl P.Bacteria and bacterial toxins as therapeutic agents for solid tumors.Curr Cancer Drug Targets2004;4:689-702

[79] Tang Y,Jiang B.Bifidobacterium bifidum-mediated specific delivery of nanoparticles for tumor therapy.Int J Nanomedicine2021;16:4643-59 PMCID:PMC8275162

[80] Kailasapathy K.Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp.Immunol Cell Biol2000;78:80-8

[81] Ryan RM,Lewis CE.Use of bacteria in anti-cancer therapies.Bioessays2006;28:84-94

[82] Wu C,Shang H.Construction of a humanized PBMC-PDX model to study the efficacy of a bacterial marker in lung cancer immunotherapy.Dis Markers2022;2022:1479246 PMCID:PMC9441396

[83] Chervin C, Gajewski TF. Microbiome-based interventions: therapeutic strategies in cancer immunotherapy.Immunooncol Technol2020;8:12-20 PMCID:PMC9216398

[84] Rezasoltani S,Asadzadeh Aghdaei H.Modulatory effects of gut microbiome in cancer immunotherapy: a novel paradigm for blockade of immune checkpoint inhibitors.Cancer Med2021;10:1141-54 PMCID:PMC7897953

[85] Longhi G,Ventura M.Microbiota and cancer: the emerging beneficial role of bifidobacteria in cancer immunotherapy.Front Microbiol2020;11:575072 PMCID:PMC7507897

[86] Shi Y,Yang K.Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling.J Exp Med2020;217:e20192282 PMCID:PMC7201921

[87] Kaźmierczak-Siedlecka K,Catalano M.Gut microbiota modulation in the context of immune-related aspects of Lactobacillus spp. and Bifidobacterium spp. in gastrointestinal cancers.Nutrients2021;13:2674 PMCID:PMC8401094

[88] Liwinski T,Ruehlemann MC.A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis.Aliment Pharmacol Ther2020;51:1417-28

[89] Hazan S,Bozkurt HS.Lost microbes of COVID-19: Bifidobacterium, Faecalibacterium depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity.BMJ Open Gastroenterol2022;9:e000871 PMCID:PMC9051551

[90] Zhang L,Ma L,Cheng B.A low abundance of Bifidobacterium but not Lactobacillius in the feces of Chinese children with wheezing diseases.Medicine2018;97:e12745 PMCID:PMC6200502

[91] van Heck JIP,Stienstra R.The gut microbiome composition is altered in long-standing type 1 diabetes and associates with glycemic control and disease-related complications.Diabetes Care2022;45:2084-94

[92] Gurung M,You H.Role of gut microbiota in type 2 diabetes pathophysiology.EBioMedicine2020;51:102590 PMCID:PMC6948163

[93] Sedighi M,Navab-Moghadam F.Comparison of gut microbiota in adult patients with type 2 diabetes and healthy individuals.Microb Pathog2017;111:362-9

[94] Wu X,Han L.Molecular characterisation of the faecal microbiota in patients with type II diabetes.Curr Microbiol2010;61:69-78

[95] Song Q,Liu W.Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol 2023; In press.

[96] Turroni F,Foroni E,Ventura M.Human gut microbiota and bifidobacteria: from composition to functionality.Antonie Van Leeuwenhoek2008;94:35-50

[97] Lin C,Zhang H.Intestinal 'infant-type' Bifidobacteria mediate immune system development in the first 1000 days of life.Nutrients2022;14:1498 PMCID:PMC9002861

[98] Alfonsetti M,d’Angelo M.Are we what we eat? Impact of diet on the gut-brain axis in Parkinson’s disease.Nutrients2022;14:380 PMCID:PMC8780419

[99] Gong H,Ren Q.The abundance of bifidobacterium in relation to visceral obesity and serum uric acid.Sci Rep2022;12:13073 PMCID:PMC9338261

[100] O’Callaghan A.Bifidobacteria and their role as members of the human gut microbiota.Front Microbiol2016;7:925 PMCID:PMC4908950